HeartBeam, Inc. (BEAT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
HeartBeam, Inc. (BEAT) trades at $0.4783 with AI Score 26/100 (Grade F). HeartBeam, Inc. is a medical technology company focused on providing telemedicine solutions for cardiac disease detection and monitoring. Market cap: $26.6M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 9, 2026Analyst Coverage for BEAT: BEAT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BEAT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BEAT: 3/3 scored disciplines lean bearish. Dominant signal: Valuation weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
HeartBeam, Inc. (BEAT) Healthcare & Pipeline Overview
HeartBeam, Inc. develops and commercializes telemedicine solutions for remote cardiac monitoring, providing diagnostic data to physicians. Their core product combines a portable ECG device with cloud-based software, targeting the growing remote patient monitoring market within the healthcare information services sector. The company aims to improve cardiac care accessibility and management.
What Is the Investment Thesis for BEAT?
HeartBeam, Inc. presents a focused investment opportunity within the growing telemedicine and remote patient monitoring market. The company's core value proposition lies in its ability to provide accessible and convenient cardiac monitoring solutions, potentially reducing the burden on traditional healthcare facilities. Key value drivers include the successful commercialization and adoption of its ECG device and cloud-based software platform. Growth catalysts include securing regulatory approvals, establishing partnerships with healthcare providers, and demonstrating clinical efficacy. However, potential risks include competition from established medical device companies, the need for continuous innovation, and the challenges of navigating the complex healthcare regulatory landscape. With a market capitalization of $26.6M and a beta of -0.64, HeartBeam is a small-cap company with potentially lower volatility than the broader market.
Based on FMP financials and quantitative analysis
BEAT Key Highlights
Focus on telemedicine solutions for cardiac disease detection and monitoring.
- Development of a credit card-sized electrocardiogram (ECG) machine for remote patient use.
- Cloud-based diagnostic software system for analyzing ECG data and providing insights to physicians.
- Addresses the rapidly growing field of remote patient monitoring.
- Incorporated in 2015, indicating a relatively young company in the medical technology sector.
Who Are BEAT's Competitors?
BEAT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | 67 |
| THKKF Think Research Corporation | $0.23 | -1.74% | $17.8M | 57 |
| AIRDF Rocket Doctor AI Inc. | $0.44 | -2.99% | $42.4M | 56 |
| VRHI Veri Medtech Holdings Inc. | $2.35 | +0.00% | $46.9M | 67 |
| BBLN Babylon Holdings Limited | $0.55 | -13.99% | $14.1M | 56 |
| CMPD CompuMed, Inc. | $7.25 | -7.70% | $9.35M | 60 |
| CRBKF Carebook Technologies Inc. | $0.03 | +0.00% | $6.84M | 64 |
| CCLD CareCloud, Inc. | $2.63 | -0.38% | $112M | 69 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BEAT's Key Strengths?
Innovative telemedicine solutions for cardiac care.
- Portable and convenient ECG device.
- Cloud-based diagnostic software system.
- Focus on remote patient monitoring.
- Experienced management team.
What Are BEAT's Weaknesses?
Limited market presence.
- Dependence on regulatory approvals.
- Competition from established medical device companies.
- Small number of employees.
What Could Drive BEAT Stock Higher?
FDA approval for HeartBeam's ECG device and software platform.
- Clinical trial results demonstrating the efficacy of HeartBeam's solutions.
- Strategic partnerships with healthcare providers and insurance companies.
- Expansion into new geographic markets.
What Are the Key Risks for BEAT?
Financial-distress signal — its Altman Z-Score of -10.49 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from established medical device companies.
- Technological obsolescence.
- Changes in healthcare regulations.
- Economic downturn affecting healthcare spending.
- Dependence on regulatory approvals and reimbursement.
What Are the Growth Opportunities for BEAT?
- Expansion into New Therapeutic Areas: HeartBeam has the opportunity to expand its technology platform beyond cardiac monitoring to address other chronic diseases that benefit from remote monitoring. This could include respiratory conditions, diabetes management, and sleep disorders. The market for remote monitoring of chronic diseases is estimated to reach $63.7 billion by 2027, presenting a significant growth opportunity for HeartBeam. Timeline: 2-3 years.
- Strategic Partnerships with Healthcare Providers: Collaborating with hospitals, clinics, and physician groups can accelerate the adoption of HeartBeam's solutions. These partnerships can provide access to a broader patient base and facilitate integration into existing healthcare workflows. The market for healthcare partnerships is growing as providers seek innovative solutions to improve patient outcomes and reduce costs. Timeline: Ongoing.
- Geographic Expansion into International Markets: HeartBeam can expand its market reach by entering international markets with similar healthcare needs and regulatory environments. This could include Europe, Asia-Pacific, and Latin America. The global market for remote patient monitoring is expected to reach $175.2 billion by 2027, offering substantial growth potential. Timeline: 3-5 years.
- Development of Advanced Analytics and AI Capabilities: Integrating advanced analytics and artificial intelligence (AI) into its cloud-based software platform can enhance the accuracy and efficiency of cardiac monitoring. This can enable earlier detection of cardiac events and personalized treatment recommendations. The market for AI in healthcare is projected to reach $34.3 billion by 2027. Timeline: 1-2 years.
- Securing Regulatory Approvals and Reimbursement: Obtaining regulatory approvals from agencies such as the FDA and securing reimbursement from insurance providers are critical for the commercial success of HeartBeam's solutions. These approvals can validate the safety and efficacy of its technology and ensure widespread adoption by healthcare providers. The market for medical device regulatory approvals is highly competitive, requiring rigorous clinical trials and data analysis. Timeline: Ongoing.
What Are BEAT's Competitive Advantages?
- Proprietary technology in ECG device and diagnostic software.
- First-mover advantage in the telemedicine cardiac monitoring market.
- Strong relationships with healthcare providers.
- Data generated from remote patient monitoring creates a valuable asset.
What Does BEAT Do?
HeartBeam, Inc., established in 2015 and headquartered in Santa Clara, California, is a medical technology company dedicated to transforming cardiac care through innovative telemedicine solutions. Recognizing the increasing need for remote patient monitoring, HeartBeam focuses on developing technologies that enable the detection and management of cardiac disease outside of traditional healthcare settings. The company's primary product is a credit card-sized electrocardiogram (ECG) device designed for easy and convenient use by patients at home. This portable ECG is paired with a cloud-based diagnostic software system that analyzes the data and provides physicians with actionable insights for patient care management. HeartBeam's solutions aim to improve the accessibility and efficiency of cardiac care, allowing for continuous monitoring and timely intervention. By providing diagnostic data to physicians, HeartBeam supports better care management of patients with cardiovascular disease, a leading cause of mortality worldwide. The company's focus on telehealth and remote patient monitoring positions it within a rapidly expanding segment of the healthcare industry, driven by technological advancements and the increasing prevalence of chronic diseases.
What Products and Services Does BEAT Offer?
- Develop telemedicine solutions for cardiac disease detection and monitoring.
- Manufacture a credit card-sized electrocardiogram (ECG) machine.
- Provide a cloud-based diagnostic software system for ECG data analysis.
- Offer remote patient monitoring services.
- Provide diagnostic data to physicians for care management.
- Focus on improving accessibility and efficiency of cardiac care.
How Does BEAT Make Money?
- Sales of ECG devices to patients and healthcare providers.
- Subscription fees for access to the cloud-based diagnostic software system.
- Partnerships with healthcare providers for remote patient monitoring services.
What Industry Does BEAT Operate In?
HeartBeam, Inc. operates within the medical technology and healthcare information services sector, a dynamic and rapidly evolving industry. The market for remote patient monitoring is experiencing significant growth, driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in telehealth technologies. The competitive landscape includes established medical device companies and emerging telehealth providers. HeartBeam's focus on cardiac care positions it within a specialized segment of this broader market. The company's success will depend on its ability to differentiate its solutions, secure regulatory approvals, and establish strong partnerships with healthcare providers.
Who Are BEAT's Key Customers?
- Patients with cardiovascular disease.
- Physicians and cardiologists.
- Hospitals and clinics.
- Healthcare providers offering remote patient monitoring services.
Company Profile
HeartBeam, Inc. operates in the Health Information Services industry within the Healthcare sector. It is headquartered in Santa Clara, United States.
Financial Health
HeartBeam, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.49 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Its free cash flow yield is -53.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.74 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -65.3%, the inverse of the P/E and a quick read on earnings relative to price.
BEAT Valuation & Market Position
With a $26.6M market cap, HeartBeam, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BEAT's quantitative score of 26/100 is below the peer average of 61/100.
Forward Outlook
Wall Street analysts project HeartBeam, Inc. revenue of about $836K for fiscal 2026, with EPS near $-0.36.
BEAT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in HeartBeam's growth potential, indicating that key stakeholders see value in the company's direction.
- Community sentiment has shifted positively, with discussions around potential breakthroughs in cardiac monitoring technology gaining traction.
- Analysts have noted an increased interest in telehealth solutions, which aligns with HeartBeam's innovative approach to heart disease diagnostics.
- The company has been actively expanding partnerships, enhancing its market presence and credibility in the healthcare sector.
Bear Case
- There are concerns about the competitive landscape, as larger firms are also investing heavily in cardiac monitoring technologies, potentially overshadowing HeartBeam.
- Social sentiment reflects skepticism about the company's ability to scale operations effectively, especially in a rapidly evolving industry.
- Recent earnings reports have raised questions about revenue sustainability, leading to a cautious outlook among some investors.
- Market chatter indicates that some community members are worried about regulatory hurdles that could delay product launches and impact growth timelines.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BEAT Latest News
-
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga · Aug 14, 2026
BEAT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BEAT.
Price Targets
Wall Street price target analysis for BEAT.
BEAT MoonshotScore
What does this score mean?
The MoonshotScore rates BEAT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Robert Eno
CEO
Robert Eno serves as the Chief Executive Officer of HeartBeam, Inc. He brings extensive experience in the medical device and healthcare industries. His background includes leadership roles in various companies, where he focused on strategic planning, product development, and commercialization. Eno's expertise spans across multiple therapeutic areas, including cardiology and remote patient monitoring. He is responsible for guiding HeartBeam's vision and growth strategy.
Track Record: Under Robert Eno's leadership, HeartBeam, Inc. has focused on developing and commercializing its innovative ECG device and cloud-based software platform. Key achievements include securing funding for research and development, establishing partnerships with healthcare providers, and advancing the company's regulatory approval process. Eno's strategic decisions have positioned HeartBeam as a player in the telemedicine cardiac monitoring market.
Common Questions About BEAT (Healthcare)
What does the AI Score mean for BEAT?
BEAT holds an AI Score of 26/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. HeartBeam, Inc. is a medical technology company focused on providing telemedicine solutions for cardiac disease detection and monitoring. Their primary product is a credit card-sized …
What does HeartBeam, Inc. do?
HeartBeam, Inc. is a medical technology company focused on developing and commercializing telemedicine solutions for the detection and monitoring of cardiac disease outside of traditional healthcare settings. Their core product is a credit card-sized electrocardiogram (ECG) machine that patients can use at home to record their heart activity.
What do analysts say about BEAT stock?
As of 2026-05-09, there is limited analyst coverage available for HeartBeam, Inc. (BEAT) due to its small market capitalization and early stage of development. Key valuation metrics are still emerging as the company focuses on commercializing its products and securing regulatory approvals.
What are the main risks for BEAT?
HeartBeam, Inc. faces several risks common to small-cap medical technology companies. These include competition from larger, more established players in the medical device industry, the need for continuous innovation to stay ahead of technological advancements, and the challenges of navigating the complex healthcare regulatory landscape.
What are the key factors to evaluate for BEAT?
HeartBeam, Inc. (BEAT) holds an AI score of 26/100 (low). presents a focused investment opportunity within the growing telemedicine and remote patient monitoring market. Not financial advice.
How frequently does BEAT data refresh on this page?
BEAT's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BEAT's recent stock price performance?
HeartBeam, Inc. (BEAT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative telemedicine solutions for cardiac care. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BEAT overvalued or undervalued right now?
HeartBeam, Inc. (BEAT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BEAT before investing?
Before investing in HeartBeam, Inc. (BEAT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The analysis is limited by the availability of financial data for HeartBeam, Inc.